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Patients With Prolonged Ischemic
hest Pain and Presumed-New Left Bundle
ranch Block Have Heterogeneous Outcomes
epending on the Presence of ST-Segment Changes
heuk-Kit Wong, MD, FACC,*† John K. French, MB, PHD, FACC,* Philip E. G. Aylward, MD, FACC,‡
alph A. H. Stewart, MD, FACC,* Wanzhen Gao, PHD,* Paul W. Armstrong, MD, FACC,§
rans J. J. Van De Werf, MD, FACC, R. John Simes, MD,¶ O. Christopher Raffel, MB,*
hristopher B. Granger, MD, FACC,# Robert M. Califf, MD, FACC,# Harvey D. White, DSC, FACC,*
or the HERO-2 Trial Investigators
uckland and Dunedin, New Zealand; Adelaide, South Australia; Edmonton, Canada; Leuven, Belgium;
ydney, Australia; and Durham, North Carolina
OBJECTIVES The purpose of this research was to examine the prognostic value of ST-segment changes
(concordant ST-segment elevation and/or precordial V1 to V3 ST-segment depression)
during presumed-new left bundle branch block (LBBB) in patients receiving fibrinolytic
therapy.
BACKGROUND These patients are often considered high-risk, but their outcome is not well-defined.
METHODS The Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial compared bivalirudin with
heparin in patients receiving streptokinase for ST-segment elevation or presumed-new
LBBB. Each patient with LBBB was matched with a control (with normal intraventricular
conduction) for age, gender, pulse rate, systolic blood pressure, Killip class, and region.
RESULTS A total of 300 patients had LBBB (92 with and 208 without ST-segment changes) and
15,340 had normal conduction. Acute myocardial infarction (AMI) occurred in 80.7% of
LBBB patients and 88.7% of controls (p 0.006). ST-segment changes were specific (96.6%)
but not sensitive (37.8%) for enzymatic diagnosis of AMI. Mortality at 30 days was similar
in LBBB patients with ST-segment changes (21.7%) and controls (25.0%, p  0.563), but
lower in LBBB patients without ST-segment changes than in controls (13.5% vs. 21.6%, p
 0.022). In the whole HERO-2 cohort, the LBBB patients with ST-segment changes had
higher mortality than patients with normal conduction (odds ratio [OR] 1.37, 95%
confidence interval [CI] 0.78 to 2.42). The LBBB patients without ST-segment changes had
lower mortality than patients with normal conduction (OR 0.52, 95% CI 0.33 to 0.80).
CONCLUSIONS ST-segment changes during LBBB are specific for the diagnosis of AMI and predict 30-day
mortality; LBBB patients without ST-segment changes have lower adjusted 30-day mortality
than those with normal conduction. Trials are required to determine the best treatment for
high-risk and low-risk patients with LBBB. (J Am Coll Cardiol 2005;46:29–38) © 2005
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.02.084by the American College of Cardiology Foundation
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Gepolarization changes occurring with left bundle branch
lock (LBBB) can obscure the classical electrocardiographic
hanges of ST-segment elevation in patients presenting
See page 39
ith acute myocardial infarction (AMI). Treatment guide-
ines recommend reperfusion therapy for patients presenting
ith LBBB and a history suggestive of AMI, regardless of
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005, accepted February 8, 2005.ssociated ST-segment changes (1,2). Although these pa-
ients have generally been considered to be at higher risk, it
s uncertain if LBBB, in itself, predicts an adverse outcome
ndependently of other prognostic factors.
When LBBB is present, delayed left ventricular activation
ccurs due to electrical activity spreading rapidly from the
erminations of the right bundle branch. Normally the ST
egment is depressed or elevated in the opposite direction to
he main QRS deflection due to secondary repolarization
hanges (3). Manifestation of concordant ST-segment ele-
ation (with a positive QRS complex) or ST-segment
epression in leads V1 to V3 (with a negative QRS complex)
uring LBBB requires large ST-segment shifts, which may
eflect severe transmural myocardial ischemia (4).
Using a raised creatine kinase-myocardial band (CK-
B) level as the “gold standard” for the diagnosis of AMI,
garbossa et al. (4) studied a cohort of patients from the
lobal Utilization of Streptokinase and Tissue Plasminogen
ctivator for Occluded Coronary Arteries (GUSTO)-I
t
h
e
s
h
s
S
t
T
e
n
i
(
r
s
i
v
e
d
M
T
P
c
n
w
e
t
w
3
t
a
m
t
e
d
n
E
c
p
c
l
s
c
w
a
M
M
M
C
S
w
u
t
i
b
c
n
a
t
(
i
m
o
w
b
c
c
t
N
t
s
w
c
m
s
t
c
c
s
a
L
a
m
p
H
a
30 Wong et al. JACC Vol. 46, No. 1, 2005
ST-Segment Changes During LBBB Predict Outcomes July 5, 2005:29–38rial, and found that two features occurring during LBBB
ad independent diagnostic value for AMI. ST-segment
levation measuring 1 mm concordant with (i.e., in the
ame direction as) the QRS complex in any lead had the
ighest diagnostic value, followed by ST-segment depres-
ion measuring 1 mm in any lead from V1 to V3.
T-segment elevation measuring 5 mm discordant with
he QRS complex was not, in itself, diagnostic of AMI.
hese criteria have recently been tested in community and
mergency room studies, and were found to be specific, but
ot sensitive, for the diagnosis of AMI (5,6). In the large,
nternational Hirulog and Early Reperfusion or Occlusion
HERO)-2 trial (7), electrocardiograms were recorded at
andomization and repeated 60 min after commencing
treptokinase, allowing identification of serial changes dur-
ng LBBB. In this substudy, we examined the prognostic
alue (for 30-day mortality) of concordant ST-segment
levation or ST-segment depression in leads V1 to V3
uring LBBB.
ETHODS
he HERO-2 trial has been described previously (7).
atients presenting with 30 min of ischemic chest dis-
omfort and either ST-segment elevation or presumed-
ew-onset LBBB (i.e., with no previous record of LBBB)
ithin 6 h of symptom onset were randomized to receive
ither bivalirudin or unfractionated heparin as adjunctive
herapy with streptokinase and aspirin. All patients gave
ritten, informed consent. The primary end point was
0-day mortality, which did not differ between the two
reatment groups. The electrocardiograms (ECG) recorded
t randomization (i.e., before fibrinolytic therapy) and 60
in after commencement of fibrinolytic therapy were sent
o a core laboratory at Green Lane Hospital for analysis by
xperienced readers. Enzymatic confirmation of AMI was
efined as a CK level exceeding twice the upper limit of
ormal (ULN) or a CK-MB level exceeding the ULN.
lectrocardiographic analysis of LBBB. The diagnostic
riteria for LBBB were a QRS duration of 0.120 s in the
resence of sinus or supraventricular rhythm, a QS or rS
omplex in lead V1, and an R-wave peak time of 0.06 s in
Abbreviations and Acronyms
AMI  acute myocardial infarction
CI  confidence interval
CK  creatine kinase
GUSTO  Global Utilization of Streptokinase and
Tissue Plasminogen Activator for Occluded
Coronary Arteries
HERO  Hirulog and Early Reperfusion or Occlusion
LBBB  left bundle branch block
OR  odds ratio
RBBB  right bundle branch block
ULN  upper limit of normaleads I, V5, or V6 associated with absence of a Q-wave in the came lead (4). The following measurements were made by a
ardiologist blinded to the patients’ treatment and outcome,
ith ST-segment deviation being measured at the J point
nd compared with the TP segment isoelectric line:
aximum magnitude of ST-segment elevation in leads
with a positive QRS complex (concordant ST-segment
elevation).
aximum magnitude of ST-segment depression in leads
V1, V2, or V3.
aximum magnitude of ST-segment elevation in leads
with a negative QRS complex (discordant ST-segment
elevation).
hange in net QRS polarity (direction) over 60 min in the
lead showing a positive QRS complex and maximum
concordant ST-segment elevation at randomization.
tatistical analysis. Patients with LBBB were compared
ith: 1) a matched control group with normal intraventric-
lar conduction, and 2) all patients with normal intraven-
ricular conduction. Each patient with LBBB at random-
zation was matched (for age, gender, pulse rate, systolic
lood pressure, and Killip class at randomization) with a
ontrol patient chosen from those in HERO-2 who had
ormal intraventricular conduction at both randomization
nd 60 min. As this substudy was performed in 46 countries,
he patients were also matched for their recruitment region
Russia, Eastern Europe, Western countries, Latin Amer-
ca, and Asia). After matching for these six variables, further
atching was done for diabetes and the time from symptom
nset to randomization.
The data are presented as proportions or median values
ith interquartile ranges where appropriate. Comparisons
etween groups were done using the chi-square test for
ategorical variables and the Mann-Whitney U test for
ontinuous variables. Comparisons between the LBBB pa-
ients and matched control patients were done using Mc-
emar’s test (for two levels) or Bowker’s test (for more than
wo levels) for categorical variables, and the Wilcoxon
igned rank test for continuous variables. McNemar’s test
as also used to compare the incidence of enzymatically
onfirmed AMI in patients randomized with LBBB and the
atched control patients. Also tested were the sensitivity,
pecificity, positive predictive accuracy, and negative predic-
ive accuracy (for diagnosing AMI) of the three different
riteria for ST-segment deviation during LBBB (i.e., con-
ordant ST-segment elevation measuring 1 mm, ST-
egment depression measuring 1 mm in leads V1 to V3,
nd discordant ST-segment elevation measuring 5 mm).
ogistic regression analysis was used to establish whether
ny of these three criteria independently predicted 30-day
ortality.
Logistic regression analysis was also done including all
atients with normal intraventricular conduction in
ERO-2 and incorporating the baseline variables described
bove, including the time from symptom onset. The model
alculations were repeated using the GUSTO prognostic
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July 5, 2005:29–38 ST-Segment Changes During LBBB Predict Outcomesisk score, which takes into account the heart rate, systolic
lood pressure, AMI location, previous AMI, and the
nteraction between age and Killip class (8).
Unadjusted and adjusted 30-day survival curves were
enerated using Cox regression analysis to visualize survival
ates for three groups of patients: LBBB with ST-segment
hanges, LBBB without ST-segment changes, and normal
ntraventricular conduction. In these models, the factor
ST-segment changes” was treated as a stratifying factor
ather than as a covariate. The GUSTO score (continuous
ariable) and region (five levels) were entered as covariates in
he adjusted model. The p values were generated by fitting
xtra Cox models, in which ST-segment change was en-
ered as a covariate rather than as a stratum, as well as the
USTO score and region. The assumption was that haz-
rds were proportional to the baseline hazard, and this was
ested graphically and statistically (data not shown). Cox
egression analysis was done using S-Plus 4.5 software
MathSoft Inc., Cambridge, Massachusetts), and the rest of
he analysis was done using SAS 8.01 software (SAS
nstitute Inc., Cary, North Carolina).
ESULTS
f the 17,073 patients randomized into HERO-2, 300
1.76%) had LBBB at randomization. Of these 300, 41 had
esolution of LBBB within 60 min (36 patients changed to
ormal intraventricular conduction and 5 changed to right
undle branch block [RBBB]). A total of 15,340 patients
ad normal intraventricular conduction at both randomiza-
ion and 60 min. Another 26 patients (25 with normal
ntraventricular conduction and 1 with RBBB at random-
zation) developed new LBBB within 60 min. Table 1
escribes the baseline characteristics, in-hospital interven-
ions, and 30-day mortality of the 300 patients with LBBB
t randomization, the 300 matched control patients, and the
5,340 patients with normal intraventricular conduction at
oth time points. Of the 300 patients with LBBB, 148
eceived bivalirudin and 152 received heparin, and their
0-day mortality rates were 16.2% and 15.8%, respectively
p  0.92).
When compared with the 15,340 patients with normal
ntraventricular conduction, patients with LBBB were older
nd had a greater prevalence of previous AMI and other
ardiovascular risk factors, a higher pulse rate, and a higher
illip classification at randomization, as reflected by a
igher GUSTO risk score. The 30-day mortality rates were
6% in patients with LBBB and 9.1% in those with normal
ntraventricular conduction (p  0.001), and approximately
0% of these deaths occurred within the first 24 h (Table 1).
owever, patients with LBBB had a lower 30-day mortality
ate than matched control patients (16% vs. 22.7%); in 67%
f matched pairs, both the LBBB patient and the control
atient survived; in 5.7% of matched pairs, both patients
ied; in 17% of matched pairs, only the control patient died; rnd in 10.3% of matched pairs, only the LBBB patient died
p  0.027).
ncidence of enzymatically confirmed AMI in patients
andomized with LBBB. Patients with LBBB had a lower
ncidence of enzymatically confirmed AMI than matched
ontrol patients (80.7% vs. 88.7%, p  0.006) or unselected
atients with normal intraventricular conduction (80.7% vs.
2.1%, p  0.001; Table 2). These differences persisted
hen deaths within 24 h were assumed to be due to AMI
nd when a lower CK cut-point (1.5 times the ULN) was
sed as the criterion for detection of myocyte necrosis
Table 2).
Peak cardiac enzyme levels were lower in patients with
BBB than in matched control patients, and this finding
as also present when only patients with enzymatically
onfirmed AMI were included in the analysis (Table 2).
sefulness of concordant ST-segment elevation or lead
1 to V3 ST-segment depression during LBBB for
iagnosis of enzymatically confirmed AMI. The criterion
f concordant ST-segment elevation measuring 1 mm on
he randomization ECG had high specificity (98.3%) but
ow sensitivity (33.5%) for the diagnosis of enzymatically
onfirmed AMI. The criterion of ST-segment depression
easuring1 mm in any of the V1 to V3 leads had similarly
igh specificity, but only 14.1% sensitivity. Lowering the
ut-point for ST-segment changes to 0.5 mm for each of
he two criteria did not improve sensitivity. When both
riteria were combined (i.e., concordant ST-segment eleva-
ion or lead V1 to V3 ST-segment depression), the specific-
ty for detection of enzymatically confirmed AMI was
6.6%, and the sensitivity was 37.2% (Table 3). The
riterion of discordant ST-segment elevation measuring 5
m had 58.6% specificity and 29.3% sensitivity.
onduction and ST-segment changes between baseline
nd 60 min. Of the 41 patients with baseline LBBB that
esolved within 60 min after commencing fibrinolytic ther-
py, 26 had ST-segment elevation at 60 min, and 15 did
ot. Together with the 26 patients who had ST-segment
levation at randomization and subsequently developed new
BBB within 60 min, a total of 52 patients had LBBB on
ne ECG and a pattern of ST-segment elevation without
BBB on the other ECG (50 had enzymatically confirmed
MI, and 1 without enzymatic confirmation of AMI died
ithin 24 h). Using these 52 cases as having a confirmed
ST-segment elevation acute coronary syndrome,” we eval-
ated the diagnostic sensitivity of ST-segment changes
uring LBBB for enzymatically confirmed AMI. The sen-
itivity of concordant ST-segment elevation measuring 1
m during LBBB was 44.2% (53.9% in the 26 patients
eveloping new LBBB within 60 min), while the sensitivity
f ST-segment depression measuring1 mm during LBBB
n any of the V1 to V3 leads was 23.1% (30.8% in the 26
atients developing new LBBB).
In 14 of the 82 patients (17%) with concordant ST-
egment elevation measuring 1 mm during LBBB at
andomization, ST-segment elevation in the lead showing
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ST-Segment Changes During LBBB Predict Outcomes July 5, 2005:29–38aximum concordant ST-segment elevation became dis-
ordant within 60 min after the start of fibrinolytic therapy
ecause the net QRS deflection became negative (Fig. 1).
T-segment changes during LBBB and 30-day mor-
ality. A total of 92 patients had concordant ST-segment
levation measuring 1 mm or lead V1 to V3 ST-segment
able 1. Baseline Demographics, In-Hospital Interventions, and
nd Versus All Patients With Normal Intraventricular Conductio
LBBB
(n  300)
emographics
Median age, yrs (IQR) 68.5 (61–75)
Male gender, % 57
istory of cardiovascular disease
Angina, % 62.7
AMI, % 30.7
Stroke, % 0.7
Transient ischemic attack, % 2
Percutaneous coronary intervention, % 0.3
Coronary bypass graft, % 0
isk factors
Smoking history
Never smoked, % 51.3
Past smoker, % 27.3
Current smoker, % 21.3
Hypertension, % 68.7
Diabetes, % 17
ecruitment region
Russia, % 36
Eastern Europe, % 42.3
Western countries, % 9.7
Latin America, % 9
Asia, % 3
ime from symptom onset to randomization
2 h, % 16
2 but 4 h, % 50
4 h, % 34
Median time, h (IQR) 3.4 (2.4–4.4)
nthropometrics
Median weight, kg (IQR) 75 (65–84)
Median height, cm (IQR) 168 (162–174)
Median body mass index, kg/m2 (IQR) 26.1 (23.8–29.2)
emodynamics
Median systolic blood pressure, mm Hg (IQR) 140 (120–160)
Median diastolic blood pressure, mm Hg (IQR) 80 (70–90)
Median heart rate, beats/min (IQR) 88 (75–101)
Killip class
I, % 54.3
II, % 26.7
III or IV, % 19
edian GUSTO risk score (IQR) 74 (63–84)
andomization to bivalirudin, % 49.3
n-hospital interventions
Percutaneous coronary intervention, % 2.7
Coronary bypass graft, % 1.3
ortality
Within 24 h, % 6.7
Within 30 days, % 16
p value for comparison between patients with left bundle branch block (LBBB) and
etween patients with LBBB and those with normal intraventricular conduction.
AMI  acute myocardial infarction; GUSTO  Global Utilization of Streptokina
ange.epression measuring 1 mm during LBBB, and 208 Satients did not (Table 4). Significantly, peak cardiac
nzyme levels were more than twice as high in patients with
T-segment changes during LBBB than in those without,
nd this finding persisted when the analysis excluded
atients without enzymatically confirmed AMI (Table 4).
Thirty-day mortality tended to be higher in patients with
ality in Patients With LBBB Versus Matched Control Patients,
Controls
n  300)
p Value
vs. LBBB*
Normal Intraventricular
Conduction
(n  15,340)
p Value
vs. LBBB†
8 (60–74) 0.013 61 (51–70) 0.001
57.7 0.593 71.8 0.001
55 0.032 46.4 0.001
24.7 0.009 14.5 0.001
0.7 1 0.4 0.321
1 0.317 0.9 0.058
1 0.317 1/2 0.277
1.3 N/A 0.8 0.286
0.182 0.001
53 38.3
30.3 44.7
16.7 17
62.7 0.089 51.4 0.001
19.3 0.463 13.7 0.101
N/A 0.012
36 35.6
42.3 34.5
9.7 15.1
9 10.2
3 4.5
0.951 0.032
15 21.1
52.3 50.5
32.7 28.4
.3 (2.4–4.3) 0.974 3.1 (2.2–4.2) 0.016
5 (67–83) 0.947 75 (68–85) 0.064
8 (160–173) 0.133 170 (164–175) 0.035
4 (24.2–29.0) 0.83 26.4 (24.2–29.3) 0.963
0 (120–156) 0.18 135 (120–150) 0.057
1 (75–90) 0.111 80 (70–90) 0.514
6 (74–100) 0.044 76 (65–88) 0.001
N/A 0.001
54.3 80.1
26.7 16.7
19 3.2
2 (61–83) 0.006 61 (50–70) 0.001
45.0 0.287 50.0 0.828
3.0 0.763 5.7 0.026
0.7 0.414 0.7 0.177
8.7 0.289 3.5 0.003
22.7 0.027 9.1 0.001
ed control patients, as generated from paired comparisons; †p value for comparison
Tissue Plasminogen Activator for Occluded Coronary Arteries; IQR  interquartileMort
n
(
6
3
7
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26.
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matchT-segment changes during LBBB than in those without
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ortality between the 92 LBBB patients with these ST-
egment changes and matched control patients (21.7% vs.
5%, p  0.563), but mortality was lower in the 208
BBB patients without these ST-segment changes than
n matched control patients (13.5% vs. 21.6%, p  0.022;
ig. 2).
redictors of 30-day mortality. On univariable analysis of
he 300 patients with LBBB, the odds ratio (OR) for 30-day
ortality in those with versus those without ST-segment
hanges (i.e., concordant ST-segment elevation measuring
1 mm or lead V1 to V3 ST-segment depression measuring
1 mm) was 1.79 (95% confidence interval [CI] 0.95 to
.37, p  0.074). The OR for 30-day mortality per 10-U
ncrease in the GUSTO risk score was 1.89 (95% CI 1.49 to
.41, p  0.0001).
On multivariable analysis, including the 300 patients with
BBB and the 15,340 patients with normal intraventricular
onduction, there was a significant association between the
resence of ST-segment changes during LBBB and 30-day
ortality (p  0.007). The ORs for 30-day mortality were
.65 (95% CI 1.31 to 5.38) in patients with versus patients
ithout ST-segment changes during LBBB, 1.37 (95% CI
.78 to 2.42) in patients with ST-segment changes during
BBB versus those with normal intraventricular conduc-
ion, and 0.52 (95% CI 0.33 to 0.80) in patients without
able 2. Proportion of Patients With Enzymatically Confirmed A
t Randomization
LBBB
(n  300)
nzymatically confirmed AMI (CK level 2
 ULN or CK-MB level ULN), %
80.7
Enzymatically confirmed AMI or early
death within 24 h, %
82.0
yocardial necrosis (CK level 1.5  ULN
or CK-MB level ULN), %
84.0
Myocardial necrosis or early death within
24 h, %
85.3
eak enzyme level expressed as multiple
of ULN‡
In all patients (IQR) 4.1 (2.0–9.1) 7.
In matched pairs of patients who both had
enzymatically confirmed AMI (IQR)
5.6 (3.0–
10.4)
8.
p value for comparison between patients with left bundle branch block (LBBB) and
etween patients with LBBB and those with normal intraventricular conduction; ‡th
n the CK level if the CK-MB level was not available.
AMI  acute myocardial infarction; IQR  interquartile range; ULN  upper l
able 3. Application of ST-Segment Criteria for the Diagnosis o
n Sensitivit
oncordant ST-segment elevation 1 mm 82 33.5 (27.6
ead V1 to V3 ST-segment depression 1 mm 35 14.1 (10.1
oncordant ST-segment elevation 1 mm or lead
V1 to V3 ST-segment depression 1 mm
92 37.2 (31.1MI  acute myocardial infarction; LBBB  left bundle branch block.T-segment changes during LBBB versus those with nor-
al intraventricular conduction. The GUSTO risk score
as also a predictor of 30-day mortality (OR 2.18 per 10-U
ncrease, 95% CI 2.09 to 2.28, p  0.001; Table 5).
When the analysis was repeated excluding patients who
ad normal enzyme levels and survived for 24 h, the ORs
ere 2.25 (95% CI 1.08 to 4.67) for LBBB with ST-segment
hanges versus LBBB without ST-segment changes, 1.36
95% CI 0.77 to 2.41) for LBBB with ST-segment changes
ersus normal intraventricular conduction, and 0.61 (95%
I 0.38 to 0.97) for LBBB without ST-segment changes
ersus normal intraventricular conduction.
Figures 3 and 4 show the unadjusted and adjusted 30-day
urvival curves for the 92 LBBB patients with concordant
T-segment elevation measuring 1 mm or lead V1 to V3
T-segment depression measuring 1 mm, the 208 LBBB
atients without these changes, and the 15,340 patients
ith normal intraventricular conduction.
ISCUSSION
his study has two major new findings. First, in patients
resenting with LBBB and a history of 30 min of
schemic chest discomfort, the presence of concordant
T-segment elevation or lead V1 to V3 ST-segment depres-
ion independently predicted higher 30-day mortality. Sec-
or Myocardial Necrosis Among Those With LBBB
rols
300)
p Value
vs. LBBB*
Normal Intraventricular
Conduction and
ST-Segment Elevation
(n  15,340)
p Value
vs. LBBB†
.7 0.006 92.1 0.001
.7 0.001 93.7 0.001
.3 0.01 93.9 0.001
.0 0.001 95.2 0.001
–14.0) 0.0001 7.5 (3.4–14.1) 0.0001
–14.9) 0.0001 8.2 (4.2–14.9) 0.0001
ed control patients, as generated from paired comparisons; †p value for comparison
k enzyme level was based on the creatine kinase (CK)-MB level where available, or
f normal.
I in the 300 Patients With LBBB at Randomization
Specificity (%)
Positive Predictive
Value (%)
Negative Predictive
Value (%)
) 98.3 (89.5–99.9) 98.8 (92.5–99.9) 26.1 (20.6–32.6)
) 98.4 (89.5–99.9) 97.1 (83.4–99.9) 21.5 (16.8–27.0)
) 96.6 (87.0–99.4) 97.8 (91.6–99.6) 26.9 (21.1–33.6)MI
Cont
(n 
88
92
91
95
2 (3.1
1 (4.0
match
e peaf AM
y (%)
–39.8
–19.2
–43.6
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lder age, previous AMI, and a higher GUSTO risk score)
han patients with normal intraventricular conduction. After
djustment for these baseline risk factors, patients with
BBB did not have a higher 30-day mortality rate. In fact,
he absence of concordant ST-segment elevation or lead V1
o V3 ST-segment depression during LBBB independently
redicted a lower 30-day mortality rate than that of patients
ith normal intraventricular conduction. Our analysis fo-
igure 1. (A) Randomization and (B) 60-min electrocardiograms in a pat
T-segment elevation because the net QRS deflection in lead V5 becameused on risk assessment at the time when patients were first meen and treatment decisions needed to be made, before the
esults of cardiac enzyme tests were available. When mul-
ivariable analysis was performed only on patients who were
ubsequently confirmed as having abnormal enzyme levels,
he findings were identical.
Over 80% of HERO-2 trial patients with LBBB had
nzymatically confirmed AMI. As in previous studies (4–
), concordant ST-segment elevation measuring 1 mm
nd lead V1 to V3 ST-segment depression measuring 1
n whom concordant ST-segment elevation in lead V5 became discordant
ive by 60 min.ient im within the LBBB morphology were both highly specific
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July 5, 2005:29–38 ST-Segment Changes During LBBB Predict Outcomesor the diagnosis of enzymatically confirmed AMI. Concor-
ant ST-segment elevation had modest sensitivity of 33.5%,
nd lead V1 to V3 ST-segment depression had only 14.1%
ensitivity. The use of a lower ST-segment cut-point of
0.5 mm did not improve diagnostic sensitivity. Discordant
T-segment elevation measuring 5 mm was neither sen-
itive (29.3%) nor specific (58.6%). In the 45-patient “val-
dation cohort” described in the original report by Sgarbossa
t al. (4), the sensitivity of either concordant ST-segment
levation or lead V1 to V3 ST-segment depression for the
iagnosis of enzymatically confirmed AMI was 36%, which
as consistent with our findings. These criteria had lower
ensitivity (20%) in emergency room and community
tudies (5,6).
There are several explanations for the relatively infre-
uent occurrence of concordant ST-segment elevation dur-
ng LBBB in patients with enzymatically confirmed AMI.
irst, some patients with enzymatically confirmed AMI and
BBB may have the “equivalent” of non–ST-segment
levation AMI. From serial electrocardiographic recordings,
e identified 52 patients who had LBBB on one ECG and
T-segment elevation without LBBB on the other ECG. In
hese 52 patients with an “ST-segment elevation acute
oronary syndrome,” the diagnostic sensitivity of concordant
T-segment elevation measuring1 mm during LBBB was
odest (44.2%).
Second, the ST segment may have risen from below the
riginal baseline during AMI, but not enough to be detect-
ble as concordant ST-segment elevation during LBBB.
he secondary repolarization changes during LBBB are
pposite in direction to those of the main QRS deflection
3), leading to a negative ST-segment baseline, and several
illimeters of ST-segment elevation during AMI from this
egative baseline may be insufficient to raise the ST segment
bove the isoelectric line.
able 4. Enzymatically Confirmed AMI and Mortality in Patien
LBBB and
Changes
nzymatically confirmed AMI 90 (97
Peak enzyme level expressed as multiple of ULN
All patients (IQR) 8.5 (4.
Patients with enzymatically confirmed AMI (IQR) 9.4 (4.
0-day mortality 20 (21
Timing of death
24-h mortality 1
Patients with enzymatically confirmed AMI 1
Causes of death† All c
Mortality between 24 h and 30 days 1
Patients with enzymatically confirmed AMI 1
Causes of death† 8 cardiac; 2 o
deaths not
ST-segment changes were defined as concordant ST-segment elevation measuring 
3 during left bundle branch block (LBBB); †the causes of in-hospital death were c
AMI  acute myocardial infarction; IQR  interquartile range; ULN  upper lThird, the QRS vector changes as AMI progresses over
a
mime. In the 17% of our patients who exhibited concordant
T-segment elevation during LBBB at randomization,
oncordant ST-segment elevation became discordant within
0 min as the net QRS complex became negative. Thus, in
ome LBBB patients who presented with a more evolved
MI, the concordant ST-segment elevation pattern may
ave evolved into a discordant ST-segment elevation pat-
ern.
In the American College of Cardiology/American Heart
ssociation guidelines (1), the combination of bundle
ranch block and a history suggestive of AMI is listed as a
lass 1 indication for fibrinolytic therapy. This recommen-
ation is based on the findings of placebo-controlled fi-
rinolytic trials (9–11), which showed that patients with
undle branch block on the randomization ECG had high
ortality and benefited significantly from fibrinolytic ther-
py, with a 21% reduction in mortality. However, these
rials did not specify whether the ECG showed RBBB or
igure 2. Thirty-day mortality in 92 patients with ST-segment changes
uring left bundle branch block (LBBB) versus matched control patients,
ith and Patients Without ST-Segment Changes* During LBBB
egment
92)
LBBB and No ST-Segment Changes*
(n  208) p Value
152 (73.1%) p  0.0001
5) 3.2 (1.5–6.2) p  0.0001
0) 4.4 (2.9–7.5) p  0.0001
28 (13.5%) p  0.067
10
6
9 cardiac and 1 from other causes; 4 of the
9 cardiac deaths had no enzymatic
confirmation of AMI
18
16
-hospital
ed
16 cardiac, 2 of whom had no enzymatic
confirmation of AMI; 1 from stroke on
day 16; 1 from other causes on day 4
or ST-segment depression measuring 1 mm in electrocardiographic leads V1 to
d as cardiac, stroke, bleeding, anaphylaxis, or other causes.
f normal.ts W
ST-S
* (n 
.8%)
0–17.
2–18.
.7%)
0
0
ardiac
0
0
ut-of
defin
1 mmnd in 208 patients without ST-segment changes during LBBB versus
atched control patients.
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hether there were associated ST-segment changes. ST-
egment elevation can be detected in patients with RBBB,
ut in those with LBBB, ST-segment changes reflecting
ransmural ischemia may be obscured by repolarization
hanges. There are, therefore, no data available from ran-
omized clinical trials that specifically demonstrate a mor-
ality reduction with fibrinolytic therapy in patients with
BBB.
In the HERO-2 trial, which specified prolonged isch-
mic chest discomfort lasting 30 min and presumed-new
BBB as inclusion criteria, enzymatically confirmed cases of
MI were about 10% less frequent in patients with LBBB
han in matched control patients. Some of these patients
ith LBBB who did not have enzymatically confirmed
Table 5. Multivariable Logistic Regression Mo
Predictors
GUSTO risk score (every 10-U rise)
ST-segment changes* during LBBB
(A) LBBB with ST-segment changes versus
LBBB without ST-segment changes
(B) LBBB with ST-segment changes versus
normal intraventricular conduction
(C) LBBB without ST-segment changes versus
normal intraventricular conduction
The association between the three groups (ST-segment chan
changes* absent during LBBB, and normal intraventricular c
from symptom onset were also entered into the model: (A) o
OR 1.38, 95% CI 0.79–2.44; (C) OR 0.51, 95% CI 0.33–0
Streptokinase and Tissue Plasminogen Activator for Occluded
by age, sex, pulse, systolic blood pressure, and Killip class: (A
(C) OR 0.53, 95% CI 0.33–0.83. The results were also sim
normal enzyme level and survived for 24 h: (A) OR 2.25, 9
95% CI 0.38–0.97. *ST-segment changes were defined as co
depression measuring 1 mm in electrocardiographic leads
igure 3. Nonadjusted 30-day survival curves in 92 patients with either con
eft bundle branch block (LBBB), 208 patients without concordant ST-se
5,340 patients with normal intraventricular conduction (p  0.029 for normal c
onduction vs. LBBB with ST-segment changes; p  0.07 for LBBB withoutMI might have had nonischemic chest discomfort or
rolonged ischemia without AMI.
When patients have concordant ST-segment elevation or
ead V1 to V3 ST-segment depression during LBBB, these
ndings are highly specific (97%) for the diagnosis of
nzymatically confirmed AMI. The use of early biomarkers
uch as myoglobin (12,13) and heart-type fatty-acid binding
rotein (14) in patients without ST-segment changes may
dentify a group of patients in whom subsequent confirma-
ion of AMI by cardiac markers is unlikely and in whom
brinolytic therapy may not prove beneficial.
In contrast with unselected HERO-2 patients with nor-
al intraventricular conduction, the patients with LBBB
ere older and had a greater prevalence of previous AMI
nd other cardiovascular risk factors, a higher pulse rate, and
for Predictors of 30-Day Mortality
OR 95% CI p Value
2.18 2.09–2.28 0.001
0.007
2.65 1.31–5.38
1.37 0.78–2.42
0.52 0.33–0.80
esent during left bundle branch block (LBBB), ST-segment
tion) was similar when the recruitment region and the time
tio (OR) 2.70, 95% confidence interval (CI) 1.33–5.49; (B)
he results were also similar when the Global Utilization of
nary Arteries (GUSTO) risk score in the model was replaced
2.73, 95% CI 1.33–5.62; (B) OR 1.44, 95% CI 0.81–2.54;
en the analysis was repeated excluding patients who had a
1.08–4.67; (B) OR 1.36, 95% CI 0.77–2.41; (C) OR 0.61,
nt ST-segment elevation measuring 1 mm or ST-segment
V3 during LBBB.
ant ST-segment elevation or lead V1 to V3 ST-segment depression during
t elevation or lead V1 to V3 ST-segment depression during LBBB, anddels
ges* pr
onduc
dds ra
.80. T
Coro
) OR
ilar wh
5% CIcord
gmenonduction vs. LBBB without ST-segment changes; p  0.001 for normal
ST-segment changes vs. LBBB with ST-segment changes).
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July 5, 2005:29–38 ST-Segment Changes During LBBB Predict Outcomeshigher Killip classification at randomization. Although
heir 30-day mortality rate was higher than that of un-
elected patients with ST-segment elevation and normal
onduction (16% vs. 9.1%, p  0.001), it was lower than
hat of matched control patients (16% vs. 22.7%, p 
.027). In patients with LBBB, concordant ST-segment
levation or lead V1 to V3 ST-segment depression during
BBB independently predicted the risk of 30-day mortality,
hich was 2.65 times higher in patients with associated
T-segment changes than in those without these features,
fter adjustment for other prognostic factors (Table 5).
hese ST-segment changes may have represented large
hifts from the original baseline ST-segment level during
BBB (3,15,16), reflecting more severe ischemia.
Although some patients with LBBB and no ST-
egment changes did not have enzymatic confirmation of
MI, this cannot fully explain their better outcome because
he results were similar when multivariable analysis was
epeated after excluding patients with normal enzyme levels
ho survived for 24 h. The better 30-day prognosis in
hese patients with LBBB and no ST-segment changes may
e at least partly explained by smaller infarct sizes as
eflected by lower peak enzyme levels, and/or by the
ossibility that their infarction was more characteristic of
on–ST-segment elevation AMI than ST-segment eleva-
ion AMI. In the North American cohort of patients with
BBB randomized into the GUSTO-I trial, 30-day mor-
ality was identical in the 131 patients with LBBB and
ontrol patients matched for age and Killip class (17), but
urther subgroup analysis of the LBBB patients was not
erformed.
Both LBBB and AMI are more common in elderly
igure 4. Adjusted 30-day survival curves in 92 patients with and 208 pa
epression during left bundle branch block (LBBB), and in 15,340 patient
BBB without ST-segment changes; p  0.08 for normal conduction vs.
hanges vs. LBBB with ST-segment changes).atients, and, with increasing longevity, the diagnostic and Banagement challenges posed by patients presenting with
BBB accompanying prolonged ischemic chest discomfort
ill arise more frequently. In the HERO-2 trial, LBBB at
he time of randomization was presumed to be new unless
he patient had a previous record of LBBB. Our findings
uggest that the presence of LBBB (even when judged
linically to be new) in a patient with symptoms compatible
ith AMI should not in itself be regarded as an indepen-
ent marker of higher risk. Instead, patients with LBBB
ay be risk-stratified by the presence or absence of concor-
ant ST-segment elevation or lead V1 to V3 ST-segment
epression.
Although patients with ST-segment changes during
BBB had a higher 30-day mortality rate than those
ithout ST-segment changes during LBBB, the latter
ubgroup of LBBB patients actually had a lower adjusted
0-day mortality rate than the majority of patients with
T-segment elevation AMI and normal intraventricular
onduction. These lower-risk patients with LBBB and no
ssociated ST-segment changes may have had no AMI, a
maller AMI, or an event more characteristic of non–ST-
egment elevation AMI with normal intraventricular con-
uction. Further studies are needed to test different man-
gement strategies in patients presenting with symptoms
ompatible with AMI accompanied by LBBB with or
ithout ST-segment changes.
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